Drug Detailing and Doctors’ Prescription Decisions: The Role of Information Content in the Face of Competitive Entry

References

• Albers S, Mantrala MK, Sridhar S (2010) Personal selling elasticities: A meta-analysis. J. Marketing Res. 47(5):840–853.Crossref, Google Scholar
• Berndt ER, Kyle M, Ling D (2003) The long shadow of patent expiration: Generic entry and Rx-to-OTC switches. Feenstra RC, Shapiro MD, eds. Scanner Data and Price Indexes (University of Chicago Press, Chicago).Crossref, Google Scholar
• Berndt ER, Bui L, Reiley DR, Urban GL (1995) Information, marketing, and pricing in the U.S. antiulcer drug market. Amer. Econom. Rev. 85(2):100–105.Google Scholar
• Bertrand M, Karlan D, Mullainathan S, Shafir E, Zinman J (2010) What’s advertising content worth? Evidence from a consumer credit marketing field experiment. Quart. J. Econom. 125(1):263–305.Crossref, Google Scholar
• Burnham KP, Anderson DR (2004) Multimodel inference: Understanding AIC and BIC in model selection. Sociol. Methods Res. 33(2):261–304.Crossref, Google Scholar
• Camacho N, De Jong M, Stremersch S (2014) Customer empowerment and adherence to expert advice. Internat. J. Res. Marketing 31(3):293–308.Crossref, Google Scholar
• Chandy RK, Tellis GJ, MacInnis DJ, Thaivanich P (2001) What to say when: Advertising appeals in evolving markets. J. Marketing Res. 38(4):399–414.Crossref, Google Scholar
• Chessa A, Murre JMJ (2007) A neurocognitive model of advertisement content and brand name recall. Marketing Sci. 26(1):130–141.Link, Google Scholar
• Ching AT (2010) Consumer learning and heterogeneity: Dynamics of demand for prescription drugs after patent expiration. Internat. J. Indust. Organ. 28(6):619–638.Crossref, Google Scholar
• Consumer Reports (2014) Evaluating statin drugs to treat: High cholesterol and heart disease. http://www.consumerreports.org/health/resources/pdf/best-buy-drugs/StatinsUpdate-FINAL.pdf.Google Scholar
• Danaher PJ, Bonfrer A, Dhar S (2008) The effect of competitive advertising interference on sales for packaged goods. J. Marketing Res. 45(2):211–225.Crossref, Google Scholar
• Dave DM (2013) Effects of pharmaceutical promotion: A review and assessment. Working paper, National Bureau of Economic Research, Cambridge, MA.Crossref, Google Scholar
• Dong X, Manchanda P, Chintagunta PK (2009) Quantifying the benefits of individual-level targeting in the presence of firm strategic behavior. J. Marketing Res. 46(2):207–221.Crossref, Google Scholar
• Fischer M, Albers S (2010) Patient- or physician-oriented marketing: What drives primary demand for prescription drugs? J. Marketing Res. 47(1):103–121.Crossref, Google Scholar
• Gatignon H, Anderson E, Helsen K (1989) Competitive reactions to market entry: Explaining interfirm differences. J. Marketing Res. 26(1):44–55.Crossref, Google Scholar
• Gelman A, Rubin DB (1992) Inference from iterative simulation using multiple sequences. Statist. Sci. 7(4):457–472.Crossref, Google Scholar
• Gelman A, Carlin JB, Stern HS, Dunson DB, Vehtari A, Rubin DB (2013) Bayesian Data Analysis, 3rd ed. (Chapman & Hall/CRC Press, Boca Raton, FL).Crossref, Google Scholar
• Geweke J (1992) Evaluating the accuracy of sampling-based approaches to the calculation of posterior moments. Bernardo JM, Berger JO, Dawid AP, Smith AFM, eds. Bayesian Statistics, Vol. 4 (Oxford University Press, Oxford, UK).Google Scholar
• Gönül FF, Carter F, Petrova E, Srinivasan K (2001) Promotion of prescription drugs and its impact on physicians’ choice behavior. J. Marketing 65(3):79–90.Crossref, Google Scholar
• Gonzalez J, Sismeiro C, Dutta S, Stern P (2008) Can branded drugs benefit from generic entry? The role of detailing and price in switching to non-bioequivalent molecules. Internat. J. Res. Marketing 25(4):247–260.Crossref, Google Scholar
• Greenland P, Lloyd-Jones D (2008) Critical lessons from the ENHANCE trial. J. Amer. Medical Assoc. 299(8):953–955.Crossref, Google Scholar
• Hanssens DM, Parsons LJ, Schultz RL (2001) Market Response Models: Econometric and Time Series Analysis, 2nd ed. (Kluwer Academic Publishers, Boston).Google Scholar
• Hullinger RA, Kruschke JK, Todd PM (2014) An evolutionary analysis of learned attention. Cognitive Sci. 39(4):1–44.Google Scholar
• Kappe ER (2014) Pharmaceutical lifecycle extension strategies. Ding M, Eliashberg J, Stremersch S, eds. Innovation and Marketing in the Pharmaceutical Industry (Springer-Verlag, New York),225–254.Crossref, Google Scholar
• Kesselheim AS, Misono AS, Lee JL, Stedman MR, Brookhart MA, Choudhry NK, Shrank WH (2008) Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: A systematic review and meta-analysis. J. Amer. Medical Assoc. 300(21):2514–2526.Crossref, Google Scholar
• Kumar V, Sriram S, Luo A, Chintagunta PK (2011) Assessing the effect of marketing investment in a business marketing context. Marketing Sci. 30(5):924–940.Link, Google Scholar
• Leeflang PSH, Wittink DR, Wedel M, Naert PA (2000) Building Models for Marketing Decisions (Kluwer Academic Publishers, Boston).Crossref, Google Scholar
• Lodish LM, Abraham M, Kalmenson S, Livelsberger J, Lubetkin B, Richardson B, Stevens ME (1995) How T.V. advertising works: A meta-analysis of 389 real world split cable T.V. advertising experiments. J. Marketing Res. 32(2):125–139.Crossref, Google Scholar
• Lohtia R, Donthu N, Hershberger EK (2003) The impact of content and design elements on banner advertising click-through rates. J. Advertising Res. 43(4):410–418.Crossref, Google Scholar
• Manchanda P, Rossi PE, Chintagunta PK (2004) Response modeling with nonrandom marketing-mix variables. J. Marketing Res. 41(4):467–478.Crossref, Google Scholar
• Mantrala MK, Albers S, Caldieraro F, Jensen O, Joseph K, Krafft M, Narasimhan C, Gopalakrishna S, Zoltners A, Lal R, Lodish L (2010) Sales force modeling: State of the field and research agenda. Marketing Lett. 21(3):255–272.Crossref, Google Scholar
• Martinez B (2004) Schering-Plough bets new cholesterol drug will fuel turnaround. Wall Street Journal (July 26), http://online.wsj.com/news/articles/SB109070283132172927.Google Scholar
• Meredith P (2003) Bioequivalence and other unresolved issues in generic drug substitution. Clinical Therapeutics 25(11):2875–2890.Crossref, Google Scholar
• Mizik N, Jacobson R (2004) Are physicians “easy marks?” Quantifying the effects of detailing and sampling on new prescriptions. Management Sci. 50(12):1704–1715.Link, Google Scholar
• Molloy W, Strang D, Guyatt G, Lexchin J, Bédard M, Dubois S, Russo R (2002) Assessing the quality of drug detailing. J. Clinical Epidemiology 55(8):825–832.Crossref, Google Scholar
• Narayanan S, Manchanda P (2009) Heterogeneous learning and the targeting of marketing communication for new products. Marketing Sci. 28(3):424–441.Link, Google Scholar
• Narayanan S, Manchanda P, Chintagunta PK (2005) Temporal differences in the role of marketing communication in new product categories. J. Marketing Res. 42(3):278–290.Crossref, Google Scholar
• Olsson E, Sporrong SK (2012) Pharmacists’ experiences and attitudes regarding generic drugs and generic substitution: Two sides of the coin. Internat. J. Pharmacy Practice 20(6):377–383.Crossref, Google Scholar
• Quirk J, Thornton M, Kirkpatrick P (2003) Rosuvastatin calcium. Nature Rev. Drug Discovery 2(10):769–770.Crossref, Google Scholar
• Reiffen D, Ward MR (2005) Generic drug industry dynamics. Rev. Econom. Statist. 87(1):37–49.Crossref, Google Scholar
• Richard O, Van Horn L (2004) Persistence in prescriptions of branded drugs. Internat. J. Indust. Organ. 22(4):523–540.Crossref, Google Scholar
• Rosenthal JS (2011) Optimal proposal distributions and adaptive MCMC. Brooks S, Gelman A, Jones G, Meng X, eds. Handbook of Markov Chain Monte Carlo (Chapman & Hall/CRC Press, Boca Raton, FL), 93–111.Crossref, Google Scholar
• Rosenthal MB, Berndt ER, Donohue JM, Epstein AM, Frank RG (2003) Demand effects of recent changes in prescription drug promotion. Cutler DM, Garber AM, eds. Frontiers in Health Policy Research, Vol. 6 (MIT Press, Cambridge, MA), 1–26.Crossref, Google Scholar
• Roughead EE, Gilbert AL, Harvey KJ (1998) Self-regulatory codes of conduct: Are they effective in controlling pharmaceutical representatives’ presentations to general medical practitioners? Internat. J. Health Services 28(2):269–279.Crossref, Google Scholar
• Shankar V (1997) Pioneers’ marketing mix reactions to entry in different competitive game structures: Theoretical analysis and empirical illustration. Marketing Sci. 16(3):271–293.Link, Google Scholar
• Shankar V (1999) New product introduction and incumbent response strategies: Their interrelationship and the role of multimarket contact. J. Marketing Res. 36(3):327–344.Crossref, Google Scholar
• Steenkamp JBEM, Van Heerde HJ, Geyskens I (2010) What makes consumers willing to pay a price premium for national brands over private labels. J. Marketing Res. 47(6):1011–1024.Crossref, Google Scholar
• Steinman MA, Harper GM, Chren M, Landefeld CS, Bero LA (2007) Characteristics and impact of drug detailing for gabapentin. PLoS Medicine 4(4):743–751.Crossref, Google Scholar
• Stremersch S, Van Dyck W (2009) Marketing of the life sciences: A new framework and research agenda for a nascent field. J. Marketing 73(4):4–30.Crossref, Google Scholar
• Stremersch S, Landsman V, Venkataraman S (2013) The relationship between DTCA, drug requests and prescriptions: Uncovering variation in specialty and space. Marketing Sci. 32(1):89–110.Link, Google Scholar
• Thomaselli R (2004) Schering, Merck fire drug-war salvo. Advertising Age (August 2), http://adage.com/article/news/schering-merck-fire-drug-war-salvo/100016/.Google Scholar
• Vakratsas D, Feinberg FM, Bass FM, Kalyanaram G (2004) The shape of advertising response functions revisited: A model of dynamic probabilistic thresholds. Marketing Sci. 23(1):109–119.Link, Google Scholar
• Venkataraman S, Stremersch S (2007) The debate on influencing doctors’ decisions: Are drug characteristics the missing link? Management Sci. 53(11):1688–1701.Link, Google Scholar
• Villas-Boas JM, Winer RS (1999) Endogeneity in brand choice models. Management Sci. 45(10):1324–1338.Link, Google Scholar
• Watanabe S (2010) Asymptotic equivalence of Bayes cross validation and widely applicable information criterion in singular learning theory. J. Machine Learn. Res. 11(12):3571–3594.Google Scholar
• Waxman HA (2005) The lessons of Vioxx—Drug safety and sales. New England J. Medicine 352(25):2576–2578.Crossref, Google Scholar
• Ziegler MG, Lew P, Singer BC (1995) The accuracy of drug information from pharmaceutical sales representatives. J. Amer. Medical Assoc. 273(16):1296–1298.Crossref, Google Scholar
• Zoltners AA, Sinha P, Lorimer SE (2008) Sales force effectiveness: A framework for researchers and practitioners. J. Personal Selling Sales Management 28(2):115–131.Crossref, Google Scholar